Lexaria Bioscience

LEXX

Market cap $17.4M

Exciting new human and animal studies designed to enhance business opportunities KELOWNA, BC / ACCESS Newswire / March 4, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the beginning of its 2026 research and development program (the "2026 R&D Program") designed to broaden pharmaceutical, intellectual property ("IP"), and business development opportunities through new and improved formulations. Information on 3 new studies from the 2026 R&D Program which are representative of the Company's primary areas of focus during at least the first three quarters of the calendar year, is being released today, however these studies do not necessarily encompass the entire 2026 R&D Program.

Company Further Examining the Pursuit of the World's First Oral Liraglutide Product KELOWNA, BC / ACCESS Newswire / February 5, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce final results from Human Pilot Study #5 (GLP-1-H25-5) (the "Study"), which compared oral DehydraTECH-liraglutide ("DHT-LIR") capsules to injected Saxenda® branded liraglutide ("SAX-LIR"). "We are extremely pleased with the results of Human Pilot Study #5," stated Richard Christopher, CEO of Lexaria.

Lexaria now has 60 patents granted around much of the world Lexaria urges shareholders to vote at upcoming 2026 Annual Meeting KELOWNA, BC / ACCESS Newswire / January 22, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce it has reached yet another important milestone in its strategy of building a strong and diverse intellectual property portfolio: the Company now has a total of 60 valid patents granted around most of the major potential markets around the world. Lexaria's previous update on patents was issued on October 9, 2025.

Lexaria now has 60 patents granted around much of the world  Lexaria urges shareholders to vote at upcoming 2026 Annual Meeting

KELOWNA, BC / ACCESS Newswire / January 12, 2026 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide this Annual Letter from its Chief Executive Officer ("CEO") Richard Christopher as a strategic update to all stakeholders. CEO Letter to Stakeholders Dear Fellow Stakeholders, I'm truly honored to deliver Lexaria's Annual Letter from the CEO following my first full year in the position.

Kelowna, British Columbia – TheNewswire - January 12, 2026 – Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW), (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to provide this Annual Letter from its Chief Executive Officer (“CEO”) Richard Christopher as a strategic update to all stakeholders.   CEO Letter to Stakeholders

KELOWNA, BC / ACCESS Newswire / December 30, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following additional secondary and exploratory endpoint final results update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the "Study" or the "Lexaria Study"), recently completed in Australia, focusing on 4 DehydraTECH™ ("DHT") study arms relative to the Rybelsus® control study arm. "We are pleased to report additional data from our first Phase 1b clinical study," stated Richard Christopher, CEO of Lexaria.

Kelowna, British Columbia – December 30, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, provides the following additional secondary and exploratory endpoint final results update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the “ Study ” or the “ Lexaria Study ”), recently completed in Australia, focusing on 4 DehydraTECH™ ( “DHT” ) study arms relative to the Rybelsus® control study arm.   “We are pleased to report additional data from our first Phase 1b clinical study,” stated Richard Christopher, CEO of Lexaria. “It adds to a growing dataset which showcases the many potential benefits of our platform technology – DehydraTECH.”

Lexaria Bioscience Corp. (NASDAQ: LEXX) on Tuesday provided an update on its Phase 1b, 12-week chronic study GLP-1-H24-4, recently completed in Australia, focusing on 4 DehydraTECH ( DHT) study arms relative to the Novo Nordisk A/S‘ (NYSE: NVO) Rybelsus (semaglutide) control study arm.

DehydraTECH-semaglutide reduced overall side effects by 48% as compared to Rybelsus® DehydraTECH-semaglutide reduced gastrointestinal side effects by 55% as compared to Rybelsus® Recent financings create runway for prospective new 2026 development opportunities KELOWNA, BC / ACCESS Newswire / December 23, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following final primary and major secondary efficacy endpoint results update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the " Study " or the " Lexaria Study "), recently completed in Australia, focusing on 4 DehydraTECH ® ( "DHT" ) study arms relative to the Rybelsus® control study arm. "We are extremely pleased to not only have successfully achieved our primary endpoint," stated Richard Christopher, CEO of Lexaria, "but to have also demonstrated obvious superiority in reducing unwanted side effects by as much as approximately half as compared to the world's only approved oral-based GLP-1 medication, Rybelsus ®.